Antibiotic use was associated with increased risk for some cancers
the ONA take:
Recurrent exposure to antibiotics may increase the risk for cancer in specific organ sites, according to a recent report published in the European Journal of Cancer.
A large population-based electronic medical record database was used to conduct nested case-control studies for 15 common malignancies. Persons with inherited cancer syndromes were excluded. Four eligible matched controls were selected for every case. In total, 125,441 cases and 490,510 matched controls were analyzed.
The findings demonstrated use of penicillin was associated with higher risk of some GI cancers, and this association was higher for those who underwent more antibiotic courses.
Penicillin, cephalosporins, or macrolides use was associated with higher risk for lung cancer; penicillin, quinolones, sulphonamides, and tetracyclines were associated with moderately increased risk for prostate cancer; and sulphonamides were modestly associated with risk for breast cancer. However, no association was found with the use of antivirals and antifungals.
Recurrent exposure to antibiotics may increase the risk for cancer in specific organ sites.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|